Myasthenia gravis (MG) is an autoimmune disorder that affects the neuromuscular junction,
leading to muscle weakness and fatigue. MG is caused by antibodies against the …

Objectives This paper reviews current and emerging therapies for multiple myeloma (MM).
Methods Narrative review. Results MM is a complex, heterogenous condition, and in recent …

Relapsed and refractory (R/R) idiopathic Multicentric Castleman disease (iMCD) is a clinical
challenge with few treatment options. In this first multicenter, prospective trial which …

Tumor bone metastasis is an important cause of tumor recurrence and death. Although bone-
targeting nanoparticles decorated with targeting ligands have shown good affinity for bone …

Human herpesvirus 8 (HHV-8)–negative idiopathic multicentric Castleman disease (iMCD)
is a rare lymphoproliferative disorder. 1 Patients with iMCD experience a wide spectrum of …

Multiple myeloma continues to be a challenging disorder to treat despite improved therapies
and the widespread use of proteasome inhibitors and immunomodulatory drugs. Although …

Multiple myeloma (MM) has witnessed improved patient outcomes through advancements in
therapeutic approaches. Notably, allogeneic stem cell transplantation, proteasome …

Carfilzomib (CFZ) is a proteasome inhibitor currently approved for the treatment of relapsed
and refractory multiple myeloma (RRMM). Multiple trials are ongoing to evaluate its efficacy …

Purpose A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone
(CVD) shows significant efficacy and manageable toxicity as induction therapy in patients …

Despite the increasing inclusion of novel agents within the multiple myeloma (MM) treatment
sequence, their role for posttransplant consolidation therapy remains unclear. We …